Neoleukin Therapeutics Investor Relations Material

Neoleukin Therapeutics Inc. is a biopharmaceutical company focused on developing immunotherapies using its proprietary de novo protein design technology. The company’s approach involves creating novel proteins to target immune system pathways, with a particular focus on cancer and inflammatory diseases. Neoleukin’s therapies aim to harness and modulate the immune system to treat diseases more effectively. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.